Axis Spine, a UK-based spinal implant company, raised £830k in funding.
The round was led by Mercia with participation from two private investors.
The company intends to use the funds to launch trials of its product in the US and start early commercialization and gain entry into the £7bn US spinal implant market.
Led by Jonathan Arcos, CEO, Axis Spine has been developing the next generation of spinal implants for three years. It expects to secure clearance from the US Food and Drug Administration (FDA) next month.